Mga Batayang Estadistika
| LEI | 5299003M2P4CIK0RF205 |
| CIK | 1237831 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Globus Medical, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Globus Medical Reports Second Quarter 2025 Results Exhibit 99.1 Globus Medical Reports Second Quarter 2025 Results AUDUBON, PA, August 7, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025. · Worldwide net sales were $745.3 million, an increase of 18.4%, or an increase of 17.6% on a constant currency basis · GAAP net income for the |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exa |
|
| August 7, 2025 |
EXHIBIT 10.2 GUARANTY SUPPLEMENT This Guaranty Supplement is dated as of June 4, 2025, and given by Nevro Corp., a Delaware corporation (the “New Guarantor”), in favor of the Administrative Agent. Reference is made to the Guaranty dated as of September 27, 2023, made by each Guarantor party thereto, in favor of the Administrative Agent (as amended, restated, supplemented, or otherwise modifi |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 21, 2025 |
Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results Exhibit 99.1 Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results AUDUBON, PA, July 21, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer effect |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 5, 2025 |
2021 Equity Incentive Plan, as amended 2021 EQUITY INCENTIVE PLAN, AS AMENDED TABLE OF CONTENTS PURPOSE5 DEFINITIONS AND CONSTRUCTION5 “Administrator5 “Applicable Accounting Standards5 “Applicable Law5 “Award5 “Award Agreement5 “Board6 “Change in Control6 “Code6 “Committee7 “Common Stock7 “Company7 “Consultant7 “Director7 “Disability7 “DRO7 “Effective Date7 “Eligible Individual7 “Employee7 “Exchange Act7 “Expiratio |
|
| May 29, 2025 |
Conflict Minerals Report of Globus Medical, Inc. Exhibit 1.01 Globus Medical, Inc. Conflict Minerals Report for the Year Ended December 31, 2024 This Conflict Minerals Report (this “Report”) of Globus Medical, Inc. (together with its subsidiaries, the “Company”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2024 to December 31, 2 |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403 (Address of |
|
| May 15, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 15, 2025 |
Globus Medical Announces $500 Million Share Repurchase Program Exhibit 99.1 Globus Medical Announces $500 Million Share Repurchase Program AUDUBON, Pa. – May 15, 2025 (GLOBE NEWSWIRE) – Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company’s outstanding common stock. “We believe the recent volatility in o |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 8, 2025 |
Globus Medical Reports First Quarter 2025 Results Exhibit 99.1 Globus Medical Reports First Quarter 2025 Results AUDUBON, PA, May 8, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. · Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basis · GAAP net income for the quarter |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Ex |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| April 3, 2025 |
Globus Medical completes acquisition of Nevro Corp. Exhibit 99.1 NEWS RELEASE Globus Medical completes acquisition of Nevro Corp. AUDUBON, Pa., April 3, 2025 – Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it completed its previously announced acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain. “We |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact n |
|
| February 20, 2025 |
Subsidiaries of Globus Medical, Inc. EXHIBIT 21.1 Subsidiaries of Globus Medical, Inc. The following is a list of our subsidiaries as of December 31, 2024, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Subsidiary Jurisdiction GNA - Globus Medical North America LLC Pennsylvania Branch Medical Group, LLC Delaware NuVasive, LL |
|
| February 20, 2025 |
Globus Compensation Recoupment Policy EXHIBIT 97.1 GLOBUS MEDICAL, INC. COMPENSATION RECOUPMENT POLICY I. Purpose The Board of Directors (“Board”) of Globus Medical, Inc. (“Globus”), as recommended by its Compensation Committee (“Committee”), has adopted this Compensation Recoupment Policy (this “Policy) as its mandatory clawback policy if a Restatement under the Applicable Rules (defined below) occurs. Any capitalized terms use |
|
| February 20, 2025 |
Description of Securities of the Registrant. EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Globus Medical, Inc. (the “Company”, “our”, “us”, or “we”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Class A common stock, par value $.001 per share. The Comp |
|
| February 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| February 20, 2025 |
Globus Medical Reports Fourth Quarter and Full Year 2024 Results Exhibit 99.1 Globus Medical Reports Fourth Quarter and Full Year 2024 Results AUDUBON, PA, February 20, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Fourth Quarter 2024: · Worldwide net sales were $657.3 million, an increase of 6.6% on an as-reported basi |
|
| February 20, 2025 |
Globus Medical, Inc. Insider Trading Policy, adopted as of February 18, 2024 EXHIBIT 19.1 GLOBUS MEDICAL, INC. INSIDER TRADING POLICY with Respect to Certain Transactions in Company Securities This document sets forth the policy of Globus Medical, Inc. and its subsidiaries (the “Company”) with respect to transactions in the Company’s securities by employees, officers and directors of, and consultants, to the Company (the “Policy”). References in this Policy to the |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission F |
|
| February 6, 2025 |
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients Exhibit 99.1 Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients AUDUBON, Pa. and REDWOOD CITY, Calif. – February 6, 2025 (GLOBE NEWSWIRE) – Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, tod |
|
| February 6, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among GLOBUS MEDICAL, INC., PALMER MERGER SUB, INC. and NEVRO CORP. Dated as of February 6, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 5 1.1 Certain Definitions 5 1.2 Certain Interpretations 18 ARTICLE II THE MERGER 20 2.1 The Merger 20 2.2 The Effective Time 20 2.3 The Closing 20 2.4 Effect of the Merger 20 2.5 Certificate o |
|
| February 6, 2025 |
Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of February 6, 2025 (the “Agreement Date”), by and among Globus Medical, Inc., a Delaware corporation (“Parent”), Nevro Corp., a Delaware corporation (the “Company”), and the undersigned stockholders of the Company (each, a “Stockholder” and, collectively, the “Stockholders”). |
|
| January 8, 2025 |
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results Exhibit 99.1 Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, PA, January 8, 2025: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657 |
|
| January 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| November 5, 2024 |
Globus Medical Reports Third Quarter 2024 Results Exhibit 99.1 Globus Medical Reports Third Quarter 2024 Results AUDUBON, PA, November 5, 2024: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024. · Worldwide net sales were $625.7 million, an increase of 63.1% · GAAP net income for the quarter was $51.8 million · GAAP diluted earning |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. |
|
| October 2, 2024 |
Valley Forge Business Center 2560 General Armistead Avenue, Audubon, PA 19403 Phone: 610. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 6, 2024 |
Globus Medical Reports Second Quarter 2024 Results Exhibit 99.1 Globus Medical Reports Second Quarter 2024 Results AUDUBON, PA, August 6, 2024: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024. · Worldwide net sales were $629.7 million, an increase of 115.9% or 117.3% on a constant currency basis · GAAP net income for the quarter was $3 |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exa |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 6, 2024 |
2021 Equity Incentive Plan, as amended 2021 EQUITY INCENTIVE PLAN, AS AMENDED TABLE OF CONTENTS Page PURPOSE5 DEFINITIONS AND CONSTRUCTION5 “Administrator5 “Applicable Accounting Standards5 “Applicable Law5 “Award5 “Award Agreement5 “Board6 “Change in Control6 “Code6 “Committee7 “Common Stock7 “Company7 “Consultant7 “Director7 “Disability7 “DRO7 “Effective Date7 “Eligible Individual7 “Employee7 “Exchange Act7 “Expi |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403 (Address of |
|
| May 31, 2024 |
Conflict Minerals Report of Globus Medical, Inc. Exhibit 1.01 Globus Medical, Inc. Conflict Minerals Report for the Year Ended December 31, 2023 This Conflict Minerals Report (this “Report”) of Globus Medical, Inc. (together with its subsidiaries, the “Company”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2023 to December 31, |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 7, 2024 |
Globus Medical Reports First Quarter 2024 Results Exhibit 99.1 Globus Medical Reports First Quarter 2024 Results AUDUBON, PA, May 7, 2024: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024. · Worldwide net sales were $606.7 million, an increase of 119.3%, or 119.8% on a constant currency basis · GAAP net loss for the quarter was $7.1 m |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Ex |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact n |
|
| February 21, 2024 |
Globus Compensation Recoupment Policy GLOBUS MEDICAL, INC. COMPENSATION RECOUPMENT POLICY I. Purpose The Board of Directors (“Board”) of Globus Medical, Inc. (“Globus”), as recommended by its Compensation Committee (“Committee”), has adopted this Compensation Recoupment Policy (this “Policy) as its mandatory clawback policy if a Restatement under the Applicable Rules (defined below) occurs. Any capitalized terms used but not immed |
|
| February 21, 2024 |
Description of Securities of the Registrant. EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Globus Medical, Inc. (the “Company”, “our”, “us”, or “we”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Class A common stock, par value $.001 per share. The Comp |
|
| February 21, 2024 |
Subsidiaries of Globus Medical, Inc. EXHIBIT 21.1 Subsidiaries of Globus Medical, Inc. The following is a list of our subsidiaries as of December 31, 2023, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X. Subsidiary Jurisdiction Globus Medical North America, Inc. Pennsylvania Branch Medical Group, LLC Delaware NuVasive, Inc. D |
|
| February 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| February 20, 2024 |
Globus Medical Reports Fourth Quarter and Full Year 2023 Results Exhibit 99.1 Globus Medical Reports Fourth Quarter and Full Year 2023 Results AUDUBON, PA, February 20, 2024: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023. Fourth Quarter 2023: · Worldwide net sales were $616.5 million, an increase of 124.6%, or 123.8% on a cons |
|
| February 14, 2024 |
GMED / Globus Medical, Inc. / Paul David C - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* Globus Medical, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 13, 2024 |
GMED / Globus Medical, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0086862-25sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* GLOBUS MEDICAL INC (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) Decembe |
|
| February 13, 2024 |
GMED / Globus Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01028-globusmedicalincclas.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Globus Medical Inc Class A Title of Class of Securities: Common Stock CUSIP Number: 379577208 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate bo |
|
| February 5, 2024 |
Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer Exhibit 99.1 Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer Pfeil takes on expanded responsibilities while Globus fuels its next phase of growth AUDUBON, Pa., Feb. 5, 2024 (GLOBE NEWSWIRE) - Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the promotion of Keith Pfeil as chief operating officer (COO) |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| January 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| January 10, 2024 |
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results Exhibit 99.1 Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, PA, January 10, 2024: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023. The company anticipates fourth quarter 2023 sales of approximately $61 |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| November 30, 2023 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Globus Medical, Inc. |
|
| November 15, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION As previously announced, on February 8, 2023, Globus Medical, Inc., (“Globus” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with NuVasive, Inc. (“NuVasive”) and Zebra Merger Sub Inc., a wholly owned subsidiary of the Company (“Merger Sub”). On September 1, 2023, pursuant to the terms |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorpo |
|
| November 7, 2023 |
Execution Version BOND HEDGE GUARANTEE THIS BOND HEDGE GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among Royal Bank of Canada, NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version WARRANT GUARANTEE THIS WARRANT GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among JPMorgan Chase Bank, National Association, New York Branch (the “Dealer”) NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version WARRANT GUARANTEE THIS WARRANT GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among Morgan Stanley & Co. |
|
| November 7, 2023 |
Execution Version BOND HEDGE GUARANTEE THIS BOND HEDGE GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among The Bank of Nova Scotia, NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version WARRANT AMENDMENT LETTER AGREEMENT THIS WARRANT AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among The Bank of Nova Scotia (the “Dealer”), NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version BOND HEDGE AMENDMENT LETTER AGREEMENT THIS BOND HEDGE AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among Royal Bank of Canada (the “Dealer”), NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version WARRANT GUARANTEE THIS WARRANT GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among Royal Bank of Canada, NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version WARRANT AMENDMENT LETTER AGREEMENT THIS WARRANT AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among Barclays Bank PLC (the “Dealer”), through its agent Barclays Capital Inc. |
|
| November 7, 2023 |
Execution Version BOND HEDGE AMENDMENT LETTER AGREEMENT THIS BOND HEDGE AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among JPMorgan Chase Bank, National Association, New York Branch (the “Dealer”), NuVasive, Inc. |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. |
|
| November 7, 2023 |
Execution Version BOND HEDGE AMENDMENT LETTER AGREEMENT THIS BOND HEDGE AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among Barclays Bank PLC (the “Dealer”), through its agent Barclays Capital Inc. |
|
| November 7, 2023 |
Execution Version WARRANT AMENDMENT LETTER AGREEMENT THIS WARRANT AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among Royal Bank of Canada (the “Dealer”), NuVasive, Inc. |
|
| November 7, 2023 |
Globus Medical Reports Third Quarter 2023 Results Exhibit 99.1 Globus Medical Reports Third Quarter 2023 Results AUDUBON, PA, November 7, 2023: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2023. The merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that clos |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2023 |
Execution Version WARRANT GUARANTEE THIS WARRANT GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among The Bank of Nova Scotia, NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version WARRANT AMENDMENT LETTER AGREEMENT THIS WARRANT AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among Morgan Stanley & Co. |
|
| November 7, 2023 |
Execution Version BOND HEDGE GUARANTEE THIS BOND HEDGE GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among Barclays Bank PLC (the “Dealer”), through its agent Barclays Capital Inc. |
|
| November 7, 2023 |
Execution Version BOND HEDGE GUARANTEE THIS BOND HEDGE GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among JPMorgan Chase Bank, National Association, New York Branch (the “Dealer”), NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version WARRANT GUARANTEE THIS WARRANT GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among Barclays Bank PLC (the “Dealer”), through its agent Barclays Capital Inc. |
|
| November 7, 2023 |
Execution Version BOND HEDGE AMENDMENT LETTER AGREEMENT THIS BOND HEDGE AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among Morgan Stanley & Co. |
|
| November 7, 2023 |
Execution Version BOND HEDGE GUARANTEE THIS BOND HEDGE GUARANTEE (this “Guarantee”), dated as of September 1, 2023, is entered into among Morgan Stanley & Co. |
|
| November 7, 2023 |
Execution Version WARRANT AMENDMENT LETTER AGREEMENT THIS WARRANT AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among JPMorgan Chase Bank, National Association, New York Branch (the “Dealer”), NuVasive, Inc. |
|
| November 7, 2023 |
Execution Version BOND HEDGE AMENDMENT LETTER AGREEMENT THIS BOND HEDGE AMENDMENT LETTER AGREEMENT (this “Letter Agreement”), dated as of September 1, 2023, is entered into among The Bank of Nova Scotia (the “Dealer”), NuVasive, Inc. |
|
| October 2, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 2, 2023 |
EXECUTION VERSION CREDIT AGREEMENT DATED AS OF SEPTEMBER 27, 2023 BETWEEN GLOBUS MEDICAL, INC. |
|
| October 2, 2023 |
Execution Version GUARANTY This Guaranty, dated as of September 27, 2023 (as amended, restated, supplemented, or otherwise modified from time to time, this “Guaranty”), is made by and between each of the Persons identified as Guarantors on the signature pages hereof (each an “Initial Guarantor”) and each other Guarantor, in favor of U. |
|
| September 11, 2023 |
GMED / Globus Medical Inc - Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Globus Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 379577208 Date of Event Which Requires Filing of this Statement: August 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| September 1, 2023 |
EX-4.2 Exhibit 4.2 Execution Version FIRST SUPPLEMENTAL INDENTURE This FIRST SUPPLEMENTAL INDENTURE, dated as of September 1, 2023 (the “First Supplemental Indenture”), is entered into among NuVasive, Inc., a Delaware corporation (the “Company”), Globus Medical, Inc., a Delaware corporation (“Parent”), and Wilmington Trust, National Association, a national banking association, as trustee (the “Tru |
|
| September 1, 2023 |
EX-99.1 Exhibit 99.1 NEWS RELEASE Globus Medical Completes Merger with NuVasive —Creates leading global musculoskeletal company— —Robust portfolio well-positioned for long-term growth and continued innovation— AUDUBON, Pa., September 1, 2023 – Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced it has completed its previously announced merger with NuVasi |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exa |
|
| August 3, 2023 |
Globus Medical Reports Second Quarter 2023 Results Exhibit 99.1 Globus Medical Reports Second Quarter 2023 Results AUDUBON, PA, August 3, 2023: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2023. · Worldwide net sales were $291.6 million, an increase of 10.6% · GAAP net income for the quarter was $57.7 million · GAAP diluted earnings per |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 8, 2023 |
2021 Equity Incentive Plan, as amended Exhibit 10.1 2021 EQUITY INCENTIVE PLAN, AS AMENDED TABLE OF CONTENTS Page PURPOSE5 DEFINITIONS AND CONSTRUCTION5 “Administrator5 “Applicable Accounting Standards5 “Applicable Law5 “Award5 “Award Agreement6 “Board6 “Change in Control6 “Code7 “Committee7 “Common Stock7 “Company7 “Consultant7 “Director7 “Disability7 “DRO7 “Effective Date7 “Eligible Individual7 “Employee7 “Exchang |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403 (Address of |
|
| May 30, 2023 |
Conflict Minerals Report of Globus Medical, Inc. Exhibit 1.01 Globus Medical, Inc. Conflict Minerals Report for the Year Ended December 31, 2022 This Conflict Minerals Report (this “Report”) of Globus Medical, Inc. (together with its subsidiaries, the “Company”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting period from January 1, 2022 to December 31, 2 |
|
| May 4, 2023 |
Globus Medical Reports First Quarter 2023 Results Exhibit 99.1 Globus Medical Reports First Quarter 2023 Results AUDUBON, PA, May 4, 2023: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2023. · Worldwide net sales were $276.7 million, an increase of 20.0%, or 21.0% on a constant currency basis · GAAP net income for the quarter was $49.1 |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Ex |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 28, 2023 |
Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive EX-99.1 Exhibit 99.1 Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive AUDUBON, Pa., April 27, 2023 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock i |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 17, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission |
|
| April 3, 2023 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 28, 2023 |
MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-270482 MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT Dear Stockholders of Globus Medical, Inc. and Stockholders of NuVasive, Inc.: As previously announced, Globus Medical, Inc. (“Globus”), NuVasive, Inc. (“NuVasive”) and Zebra Merger Sub, Inc., a wholly owned subsidiary of Globus (“Merger Sub”), entered into an Agreement a |
|
| March 24, 2023 |
CORRESP March 24, 2023 VIA EDGAR Office of Industrial Applications and Services Division of Corporation Finance U. |
|
| March 24, 2023 |
Consent of Goldman Sachs & Co. LLC. EX-99.1 Exhibit 99.1 200 West Street | New York, NY 10282-2198 Tel: 212-902-1000 | Fax: 212-902-3000 March 24, 2023 Board of Directors Globus Medical, Inc. 2560 General Armistead Avenue Audubon, PA 19403-5214 Re: Amendment No. 1 to Registration Statement on Form S-4 of Globus Medical, Inc. (File No. 333-270482), filed March 24, 2023 (the “Amended Registration Statement”) Ladies and Gentlemen: Refe |
|
| March 24, 2023 |
Consent of BofA Securities, Inc. EX-99.2 Exhibit 99.2 Consent of BofA Securities, Inc. March 24, 2023 Board of Directors NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Members of the Board: We hereby consent to the inclusion of our opinion letter, dated February 8, 2023, to the Board of Directors of NuVasive, Inc. (“NuVasive”) as Annex D to, and to the reference to such opinion letter under the headings “SUMMARY — |
|
| March 24, 2023 |
Form of Proxy Card for Special Meeting of NuVasive, Inc. EX-99.4 Exhibit 99.4 YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: INTERNET Go To: www.proxypush.com/NUVA • Cast your vote online • Have your Proxy Card ready P.O. BOX 8016, CARY, NC 27512-9903 • Follow the simple instructions to record your vote PHONE Call 1-866-217-7017 • Use any touch-tone telephone • Have your Proxy Card ready • Follow the simple recorded instructions MAIL • Mark, sign and date your |
|
| March 24, 2023 |
As filed with the Securities and Exchange Commission on March 24, 2023 S-4/A Table of Contents As filed with the Securities and Exchange Commission on March 24, 2023 Registration No. |
|
| March 24, 2023 |
Form of Proxy Card for Special Meeting of Globus Medical, Inc. EX-99.3 Exhibit 99.3 SCAN TO VIEW MATERIALS & VOTE w VOTE BY INTERNET—www.proxyvote.com or scan the QR Barcode above C/O BROADRIDGE Use the Internet to transmit your voting instructions and for electronic delivery of P.O. BOX 1342 information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting BRENTWOOD, NY 11717 date. Have your proxy card in hand when you access the web si |
|
| March 16, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 to Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| March 13, 2023 |
Consent of BofA Securities, Inc. Exhibit 99.2 Consent of BofA Securities, Inc. March 10, 2023 Board of Directors NuVasive, Inc. 7475 Lusk Boulevard San Diego, California 92121 Members of the Board: We hereby consent to the inclusion of our opinion letter, dated February 8, 2023, to the Board of Directors of NuVasive, Inc. (“NuVasive”) as Annex D to, and to the reference to such opinion letter under the headings “SUMMARY — Opinion |
|
| March 13, 2023 |
S-4 Table of Contents As filed with the Securities and Exchange Commission on March 10, 2023 Registration No. |
|
| March 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Globus Medical, Inc. |
|
| March 13, 2023 |
Consent of Goldman Sachs & Co. LLC. EX-99.1 Exhibit 99.1 200 West Street | New York, NY 10282-2198 Tel: 212-902-1000 | Fax: 212-902-3000 March 10, 2023 Board of Directors Globus Medical, Inc. 2560 General Armistead Avenue Audubon, PA 19403-5214 Re: Registration Statement on Form S-4 of Globus Medical, Inc., filed March 10, 2023 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated Februa |
|
| February 22, 2023 |
425 1 d472555d425.htm 425 Filed by Globus Medical, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Date: February 22, 2023 Globus Medical, Inc. Q4 2022 Earnings Call Transcript February 21, 2023 Company Participants Brian Kearns - Senior Vice |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| February 21, 2023 |
Annual Report on Form 10-K for the year-ended December 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact n |
|
| February 21, 2023 |
Globus Medical Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 Globus Medical Reports Fourth Quarter and Full Year 2022 Results AUDUBON, PA, February 21, 2023: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022: · Worldwide net sales were $274.5 million, an increase of 9.8%, or 11.7% on a constant |
|
| February 21, 2023 |
EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Globus Medical, Inc. (the “Company”, “our”, “us”, or “we”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Class A common stock, par value $.001 per share. The Comp |
|
| February 21, 2023 |
EXHIBIT 21.1 Subsidiaries of Globus Medical, Inc. The following is a list of our subsidiaries as of December 31, 2022. Certain subsidiaries are not named because they were not significant in the aggregate. Subsidiary Jurisdiction Globus Medical North America, Inc. Pennsylvania Branch Medical Group, LLC Delaware Transplant Technologies of Texas, Ltd. Texas Human Biologics of Texas, Ltd. T |
|
| February 14, 2023 |
GMED / Globus Medical Inc / Paul David C - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* Globus Medical, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2023 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* GLOBUS MEDICAL INC (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 9, 2023 |
Filed by Globus Medical, Inc. pursuant to Rule 425 425 1 d432829d425.htm 425 Filed by Globus Medical, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: NuVasive, Inc. Commission File No.: 000-50744 Date: February 9, 2023 The following e-mail was sent to all employees of Globus Medical, Inc., on February 9, 2023. Sent on behalf of Dan Scavil |
|
| February 9, 2023 |
Exhibit 99.2 Globus Medical and NuVasive to Combine in All-Stock Transaction to Create Innovative Global Musculoskeletal Company Focused on Patient Care Capitalizes on complementary global commercial organizations and accelerates Globus Medical’s and NuVasive’s globalization strategies to increase customer reach and deepen surgeon relationships Brings together innovative technologies to create com |
|
| February 9, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission F |
|
| February 9, 2023 |
GMED / Globus Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Globus Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 379577208 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission F |
|
| February 9, 2023 |
425 1 d447800d425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of in |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission F |
|
| February 9, 2023 |
EX-99.1 Combining to create an innovative global musculoskeletal company February 9, 2023 Exhibit 99.1 Legal disclaimers No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any |
|
| February 9, 2023 |
Exhibit 10.1 EXECUTION VERSION VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made and entered into as of February 8, 2023 (the “Agreement Date”), by and among (i) Globus Medical, Inc., a Delaware corporation (“Parent”), (ii) NuVasive, Inc., a Delaware corporation (the “Company”), and (iii) David Paul and Sonali Paul (collectively, the “Stockholders”). Each of |
|
| February 9, 2023 |
Exhibit 2.1 [Omitted] - Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among GLOBUS MEDICAL, INC., ZEBRA MERGER SUB, INC., and NUVASIVE, INC. dated as of February 8, 2023 |
|
| November 8, 2022 |
Globus Medical Reports Third Quarter 2022 Results Exhibit 99.1 ? ? Globus Medical Reports Third Quarter 2022 Results ? AUDUBON, PA, November 8, 2022: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2022. ? ? Worldwide net sales were $254.1 million, an increase of 10.6%, or 12.6% on a constant currency basis ? GAAP net income for the quarter w |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. |
|
| August 4, 2022 |
Globus Medical Reports Second Quarter 2022 Results Exhibit 99.1 ? ? Globus Medical Reports Second Quarter 2022 Results ? AUDUBON, PA, August 4, 2022: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2022. ? ? Worldwide net sales were $263.6 million, an increase of 5.0% as reported, and an increase of 6.5% on a constant currency basis, compared to th |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exa |
|
| August 4, 2022 |
EXHIBIT 10.1 ? SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?) is entered into as of August 3, 2022, by and among GLOBUS MEDICAL, INC., a Delaware corporation (the ?Company?), GLOBUS MEDICAL NORTH AMERICA, INC., a Delaware corporation, (?North America?, and, together with the Company, the ?Borrowers?) and CITIZENS BANK, N.A., as Lender. W I T N E S |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 3, 2022 |
Exhibit 10.1 2021 EQUITY INCENTIVE PLAN, AS AMENDED TABLE OF CONTENTS Page PURPOSE5 ?DEFINITIONS AND CONSTRUCTION5 ??Administrator5 ??Applicable Accounting Standards5 ??Applicable Law5 ??Award5 ??Award Agreement5 ??Board6 ??Change in Control6 ??Code6 ??Committee7 ??Common Stock7 ??Company7 ??Consultant7 ??Director7 ??Disability7 ??DRO7 ??Effective Date7 ??Eligible Individual7 ??Employee7 ??Exchang |
|
| May 27, 2022 |
Conflict Minerals Report of Globus Medical, Inc. EX-1.01 2 gmed-20220527xex101.htm EX-1.01 Exhibit 1.01 Globus Medical, Inc. Conflict Minerals Report for the Year Ended December 31, 2021 This Conflict Minerals Report (this “Report”) of Globus Medical, Inc. (together with its subsidiaries, the “Company”) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (“Rule 13p-1”), for the reporting per |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ? GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) ? DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) ? 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403 (Address of |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Ex |
|
| May 10, 2022 |
Globus Medical Reports First Quarter 2022 Results Exhibit 99.1 ? ? Globus Medical Reports First Quarter 2022 Results ? AUDUBON, PA, May 10, 2022: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the first quarter ended March 31, 2022. ? ? Worldwide net sales were $230.5 million, an increase of 1.4% as compared to the first quarter of 2021 ? GAAP net income for the quarter wa |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2022 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 21, 2022 |
Schedule 14A filed on April 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 21, 2022 |
Globus Medical Reports CEO Transition and Preliminary First Quarter 2022 Sales Results Exhibit 99.1 ? ? Globus Medical Reports CEO Transition and Preliminary First Quarter 2022 Sales Results ? AUDUBON, PA, April 21, 2022: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the resignation of President and Chief Executive Officer, Dave Demski, after nearly 20 years with the company, with the last four and a half years as its CEO. The Board |
|
| March 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2022 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 4, 2022 |
Globus Medical Announces the Expansion of its Share Repurchase Program Exhibit 99.1 ? ? Globus Medical Announces the Expansion of its Share Repurchase Program ? AUDUBON, PA, March 4, 2022 (GLOBE NEWSWIRE) - Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has expanded the Company?s share repurchase program by authorizing the repurchase of an additional $200 million of the Company?s common stoc |
|
| February 17, 2022 |
Description of Securities of the Registrant. EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? As of December 31, 2021, Globus Medical, Inc. (the ?Company?, ?our?, ?us?, or ?we?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): Class A common stock, par value $.001 per share. The Comp |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact n |
|
| February 17, 2022 |
Globus Medical Reports Fourth Quarter and Full Year 2021 Results Exhibit 99.1 ? ? Globus Medical Reports Fourth Quarter and Full Year 2021 Results ? AUDUBON, PA, February 17, 2022: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2021. ? Fourth Quarter 2021: ? Worldwide net sales were $250.0 million, an increase of 7.1% as compared to the four |
|
| February 17, 2022 |
Subsidiaries of Globus Medical, Inc. EXHIBIT 21.1 ? Subsidiaries of Globus Medical, Inc. ? ? The following is a list of our subsidiaries as of December 31, 2021. Certain subsidiaries are not named because they were not significant in the aggregate. ? ? Subsidiary Jurisdiction Globus Medical North America, Inc. Pennsylvania Branch Medical Group, LLC Delaware Transplant Technologies of Texas, Ltd. Texas Human Biologics of Texas, Ltd. T |
|
| February 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| February 10, 2022 |
GMED / Globus Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Globus Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 379577208 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 9, 2022 |
GMED / Globus Medical Inc / Paul David C - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* Globus Medical, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 4, 2022 |
GMED / Globus Medical Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Globus Medical, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| December 16, 2021 |
As filed with the Securities and Exchange Commission on December 16, 2021 As filed with the Securities and Exchange Commission on December 16, 2021 ? Registration No. |
|
| December 16, 2021 |
Exhibit 99.5 GLOBUS MEDICAL, INC. 2021 EQUITY INCENTIVE PLAN ? NOTICE OF RESTRICTED STOCK UNIT GRANT ? ? ? ? ? ? Grant Number ? You have been awarded Restricted Stock Units, each of which represents the right to receive one share of Class A Common Stock of Globus Medical, Inc. (the ?Company?), pursuant to the Globus Medical, Inc. 2021 Equity Incentive Plan, as amended from time to time (the ?Plan? |
|
| December 16, 2021 |
Exhibit 99.7 GLOBUS MEDICAL, INC. 2021 EQUITY INCENTIVE PLAN ? NOTICE OF RESTRICTED STOCK GRANT ? ? ? ? ? ? Grant Number ? You have been awarded shares (?Shares?) of Class A Common Stock of Globus Medical, Inc. (the ?Company?), subject to certain restrictions as described in the attached Restricted Stock Agreement (the ?Restricted Stock?), pursuant to the Globus Medical, Inc. 2021 Equity Incentive |
|
| December 16, 2021 |
Exhibit 99.6 GLOBUS MEDICAL, INC. 2021 EQUITY INCENTIVE PLAN ? NOTICE OF NONQUALIFIED STOCK OPTION GRANT ? ? ? Grant Date ? Grant Number ? You have been granted a nonqualified stock option (the ?Option?) to purchase shares of the Class A Common Stock of Globus Medical, Inc. (the ?Company?) pursuant to the Globus Medical, Inc. 2021 Equity Incentive Plan, as amended from time to time (the ?Plan?), a |
|
| December 16, 2021 |
Exhibit 99.8 GLOBUS MEDICAL, INC. 2021 EQUITY INCENTIVE PLAN ? NOTICE OF INCENTIVE STOCK OPTION GRANT ? ? ? ? ? ? Grant Number ? You have been granted an incentive stock option (the ?Option?) to purchase shares of the Class A Common Stock of Globus Medical, Inc. (the ?Company?) pursuant to the Globus Medical, Inc. 2021 Equity Incentive Plan, as amended from time to time (the ?Plan?), as follows: ? |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. |
|
| November 4, 2021 |
Globus Medical Reports Third Quarter 2021 Results Exhibit 99.1 ? ? Globus Medical Reports Third Quarter 2021 Results ? AUDUBON, PA, November 4, 2021: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2021. ? ? Worldwide net sales were $229.7 million, an increase of 6.3% as compared to the third quarter of 2020 ? ? GAAP net income for the quarte |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 4, 2021 |
EXHIBIT 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this ?Amendment?) is entered into as of August 4, 2021, by and among GLOBUS MEDICAL, INC., a Delaware corporation (the ?Company?), GLOBUS MEDICAL NORTH AMERICA, INC., a Pennsylvania corporation, (?North America?, and, together with the Company, the ?Borrowers?) and CITIZENS BANK, N.A., as Lender. W I T N E S |
|
| August 4, 2021 |
Globus Medical Reports Second Quarter 2021 Results Exhibit 99.1 ? ? Globus Medical Reports Second Quarter 2021 Results ? AUDUBON, PA, August 4, 2021: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2021. ? ? Worldwide net sales were $251.0 million, an increase of 68.6% as compared to the second quarter of 2020 ? ? GAAP net income for the quarter wa |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exa |
|
| August 4, 2021 |
EXHIBIT 3.1 ? ? Amendment to Bylaws ? The Company?s Amended and Restated Bylaws shall be amended to add the following as a new Section 8.14 of the Amended and Restated Bylaws: ? 8.14Federal Forum Selection ? Unless the corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, |
|
| June 4, 2021 |
Exhibit 10.1 GLOBUS MEDICAL, INC. ? 2021 EQUITY INCENTIVE PLAN ? TABLE OF CONTENTS Page ? ARTICLE 1. PURPOSE 1 ? ARTICLE 2. DEFINITIONS AND CONSTRUCTION 1 ? 2.1 ?Administrator 1 2.2 ?Applicable Accounting Standards 1 2.3 ?Applicable Law 1 2.4 ?Award 1 2.5 ?Award Agreement 2 2.6 ?Board 2 2.7 ?Change in Control 2 2.8 ?Code 3 2.9 ?Committee 3 2.1 ?Common Stock 3 2.11 ?Company 3 2.12 ?Consultant 3 2.1 |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 28, 2021 |
Conflict Minerals Report of Globus Medical, Inc. Exhibit 1.01 Globus Medical, Inc. Conflict Minerals Report for the Year Ended December 31, 2020 This Conflict Minerals Report (this ?Report?) of Globus Medical, Inc. (the ?Company?) has been prepared pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (?Rule 13p-1?), for the reporting period from January 1, 2020 to December 31, 2020. Rule 13p-1 requires disclos |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ? GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) ? DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) ? 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403 (Address of |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Ex |
|
| May 4, 2021 |
Globus Medical Reports First Quarter 2021 Results Exhibit 99.1 ? ? Globus Medical Reports First Quarter 2021 Results ? AUDUBON, PA, May 4, 2021: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2021. ? ? Worldwide net sales were $227.3 million, an increase of 19.3% as compared to the first quarter of 2020 ? ? GAAP net income for the quarter was $4 |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? ? Filed by the Registrant ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| February 17, 2021 |
Subsidiaries of Globus Medical, Inc. EXHIBIT 21.1 ? Subsidiaries of Globus Medical, Inc. ? ? The following is a list of our subsidiaries as of December 31, 2020. Certain subsidiaries are not named because they were not significant in the aggregate. ? ? Subsidiary Jurisdiction Globus Medical North America, Inc. Pennsylvania Branch Medical Group, LLC Delaware Transplant Technologies of Texas, Ltd. Texas Human Biologics of Texas, Ltd. T |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact n |
|
| February 17, 2021 |
Description of Securities of the Registrant. EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? As of December 31, 2020, Globus Medical, Inc. (the ?Company?, ?our?, ?us?, or ?we?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): Class A common stock, par value $.001 per share. The Comp |
|
| February 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| February 17, 2021 |
Globus Medical Reports Fourth Quarter and Full Year 2020 Results Exhibit 99.1 ? ? Globus Medical Reports Fourth Quarter and Full Year 2020 Results ? AUDUBON, PA, February 17, 2021: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2020. ? Fourth Quarter 2020: ? Worldwide net sales were $233.4 million, an increase of 10.3% as compared to the fou |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Globus Medical, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Globus Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 379577208 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Globus Medical, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| October 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| October 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. |
|
| October 28, 2020 |
Globus Medical Reports Third Quarter 2020 Results Exhibit 99.1 Globus Medical Reports Third Quarter 2020 Results AUDUBON, PA, October 28, 2020: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2020. · Worldwide net sales were $216.1 million, an increase of 10.1% as compared to the third quarter of 2019 · GAAP net income was $44.2 mil |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 10, 2020 |
EXHIBIT 10.1 EXECUTION VERSION CREDIT AGREEMENT dated as of August 6, 2020 among GLOBUS MEDICAL, INC. And GLOBUS MEDICAL NORTH AMERICA, INC. as the Borrowers, and CITIZENS BANK, N.A., as the Lender TABLE OF CONTENTS Page Article 1 Definitions and Rules of Construction 1 Section 1.1 Definitions 1 Section 1.2 Classification of Loans 29 Section 1.3 Terms Generally 29 Section 1 |
|
| August 5, 2020 |
EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into this day of August, 2020 (the “Effective Date”), by and between Globus Medical, Inc., a Delaware corporation with its principal office in Montgomery County, Pennsylvania (the “Company”), and Kelly Huller, a resident of Pennsylvania (“Executive”), hereinafter collectively refer |
|
| August 5, 2020 |
EXHIBIT 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into this day of August, 2020 (the “Effective Date”), by and between Globus Medical, Inc., a Delaware corporation with its principal office in Montgomery County, Pennsylvania (the “Company”), and Keith Pfeil, a resident of Pennsylvania (“Executive”), hereinafter collectively referr |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exa |
|
| August 5, 2020 |
Globus Medical Reports Second Quarter 2020 Results Exhibit 99.1 Globus Medical Reports Second Quarter 2020 Results AUDUBON, PA, August 5, 2020: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the second quarter ended June 30, 2020. · Worldwide sales were $148.9 million, a decrease of 23.4% as reported · Second quarter net loss was $20.8 million · Diluted earnings |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2020 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 4, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403 (Address of p |
|
| May 8, 2020 |
GMED / Globus Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Globus Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 379577208 Date of Event Which Requires Filing of this Statement: April 30, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru |
|
| May 7, 2020 |
FOURTH AMENDMENT TO CREDIT AGREEMENT THIS AMENDMENT TO CREDIT AGREEMENT (this "Amendment") dated March 13, 2020, is entered into by and between GLOBUS MEDICAL, INC. |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Ex |
|
| May 7, 2020 |
Globus Medical Reports First Quarter 2020 Results Exhibit 99.1 Globus Medical Reports First Quarter 2020 Results AUDUBON, PA, May 7, 2020: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the first quarter ended March 31, 2020. · Worldwide sales were $190.6 million, an increase of 4.2% as reported · First quarter net income was $25.9 million · Diluted earnings pe |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 12, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2020 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 12, 2020 |
Globus Medical Announces $200 Million Share Repurchase Program Globus Medical Announces $200 Million Share Repurchase Program AUDUBON, PA, March 11, 2020 (GLOBE NEWSWIRE) – Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, today announced the Board of Directors authorized the repurchase of $200 million of the Company’s common stock. |
|
| March 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS ME |
|
| February 20, 2020 |
Description of Securities of the Registrant. DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Globus Medical, Inc. |
|
| February 20, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| February 20, 2020 |
Subsidiaries of Globus Medical, Inc. EXHIBIT 21.1 Subsidiaries of Globus Medical, Inc. The following is a list of our subsidiaries as of December 31, 2019. Certain subsidiaries are not named because they were not significant in the aggregate. Subsidiary Jurisdiction Globus Medical North America, Inc. Pennsylvania Branch Medical Group, LLC Delaware Transplant Technologies of Texas, Ltd. Texas Human Biologics of Texas, Ltd. T |
|
| February 20, 2020 |
Globus Medical Reports Fourth Quarter and Full Year 2019 Results Exhibit 99.1 Globus Medical Reports Fourth Quarter and Full Year 2019 Results AUDUBON, PA, February 20, 2020: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2019. Fourth Quarter: · Worldwide sales increased 8.0% as reported to $211.7 million · Fourth quarter net income w |
|
| February 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exact n |
|
| February 12, 2020 |
GMED / Globus Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Globus Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 379577208 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| February 7, 2020 |
GMED / Globus Medical, Inc. / Paul David C - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Globus Medical, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 28, 2020 |
GMED / Globus Medical, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Globus Medical, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 379577208 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 8, 2020 |
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, PA, January 8, 2020: Globus Medical, Inc. |
|
| January 8, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2020 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2019 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| December 13, 2019 |
Globus Medical Announces Board of Director Addition and Departure Globus Medical Announces Board of Director Addition and Departure AUDUBON, PA, December 13, 2019: Globus Medical, Inc. |
|
| November 6, 2019 |
Globus Medical Reports Third Quarter 2019 Results `Exhibit 99.1 Globus Medical Reports Third Quarter 2019 Results AUDUBON, PA, November 6, 2019: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the third quarter ended September 30, 2019. · Worldwide sales were $196.2 million, an increase of 15.9% as reported · Third quarter net income was $38.3 million · Diluted e |
|
| November 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File |
|
| November 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. |
|
| August 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 1, 2019 |
Globus Medical Reports Second Quarter 2019 Results Exhibit 99.1 Globus Medical Reports Second Quarter 2019 Results AUDUBON, PA, August 1, 2019: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the second quarter ended June 30, 2019. · Worldwide sales were $194.5 million, an increase of 12.2% as reported · Second quarter net income was $38.2 million · Diluted earnin |
|
| August 1, 2019 |
REVOLVING LINE OF CREDIT NOTE $125,000,000.00Conshohocken, Pennsylvania May 22, 2019 FOR VALUE RECEIVED, the undersigned GLOBUS MEDICAL, INC. and GLOBUS MEDICAL NORTH AMERICA, INC. ("Borrower")promises to pay to the order of WELLS FARGO BANK, NATIONAL ASSOCIATION ("Bank") at its office at MAC Y1392-080 , 300 Barr Harbor Drive, 8111 Floor , Suite 850, Conshohocken, Pennsylvania 19428, or at suc |
|
| August 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-35621 GLOBUS MEDICAL, INC. (Exa |
|
| June 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 27, 2019 GLOBUS MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35621 (Commission File Number) 04 |
|
| June 27, 2019 |
Globus Medical Appoints Keith Pfeil as Senior Vice President and CFO Globus Medical Appoints Keith Pfeil as Senior Vice President and CFO AUDUBON, PA: June 27, 2019: Globus Medical, Inc. |
|
| June 6, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 5, 2019 GLOBUS MEDICAL, INC. (Exact name of Registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35621 (Commission File Number) 04- |
|
| May 30, 2019 |
GMED / Globus Medical, Inc. SD - - SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT GLOBUS MEDICAL, INC. (Exact name of registrant as specified in charter) DELAWARE 001-35621 04-3744954 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403 (Address of principal executive o |
